CJC-1295 with DAC vs without DAC: Modified GHRH Research Comparison
Quick Summary
CJC-1295 exists in two distinct forms: with Drug Affinity Complex (DAC) and without DAC (also called Mod GRF 1-29). The DAC modification enables albumin binding for extended half-life, while the non-DAC version mimics more physiological GH pulsatility. Understanding the pharmacokinetic and pharmacodynamic differences between these two forms is essential for growth hormone research.
CJC-1295 (with DAC)
Research Overview CJC-1295 (no DAC), frequently referred to in the scientific literature as Modified GRF (1-29) or Mod GRF 1-29, is a synthetic peptide analog of endogenous growth hormone-releasing hormone (GHRH). It is derived from the first 29 amino acids...
CJC-1295 (without DAC)
Research Overview CJC-1295 (no DAC), frequently referred to in the scientific literature as Modified GRF (1-29) or Mod GRF 1-29, is a synthetic peptide analog of endogenous growth hormone-releasing hormone (GHRH). It is derived from the first 29 amino acids...
Research Comparison: CJC-1295 (with DAC) vs CJC-1295 (without DAC)
| Dimension | CJC-1295 (with DAC) | CJC-1295 (without DAC) |
|---|---|---|
| Full Name | CJC-1295 with Drug Affinity Complex (DAC) | Modified GRF(1-29) / CJC-1295 without DAC |
| Modification | Lysine-linked maleimidopropionic acid (MPA) for albumin binding | Four amino acid substitutions for DPP-IV resistance |
| Half-Life | ~8 days (due to albumin binding) | ~30 minutes |
| GH Release Pattern | Sustained, continuous GH elevation | Pulsatile GH release (more physiological) |
| Dosing Frequency in Studies | Weekly or bi-weekly (long-acting) | Multiple times daily (short-acting) |
| IGF-1 Response | 2-3x sustained increase over baseline | Transient 2-3x increase per dose |
| GH Bleed Effect | Continuous GH elevation may cause desensitization | Pulsatile pattern preserves receptor sensitivity |
| Synergy with GHRPs | Less commonly paired (sustained action already) | Frequently studied with Ipamorelin/GHRP-6 for synergistic GH release |
| Clinical Development | Phase II trials by ConjuChem (discontinued 2006) | Research use only; no formal clinical trials |
| Research Preference | Long-duration studies requiring steady GH elevation | Studies requiring physiological GH pulsatility |
Chemical Properties Comparison
| Property | CJC-1295 (with DAC) | CJC-1295 (without DAC) |
|---|---|---|
| Molecular Formula | C₁₅₂H₂₅₂N₄₄O₄₂ | C₁₅₂H₂₅₂N₄₄O₄₂ |
| Molecular Weight | 3367.95 g/mol | 3367.95 g/mol |
| CAS Number | 863288-34-0 | 863288-34-0 |
| Amino Acid Sequence | — | — |
| PubMed Citations | 16 referenced | 16 referenced |
Explore Full Research Profiles
CJC-1295 (with DAC)
Research Overview CJC-1295 (no DAC), frequently referred to in the scientific literature as Modified GRF (1-29) or Mod GRF 1-29, is a synthetic peptide analog of endogenous growth hormone-releasing hormone (GHRH). It is derived from the first 29 amino acids...
CJC-1295 (without DAC)
Research Overview CJC-1295 (no DAC), frequently referred to in the scientific literature as Modified GRF (1-29) or Mod GRF 1-29, is a synthetic peptide analog of endogenous growth hormone-releasing hormone (GHRH). It is derived from the first 29 amino acids...
More Peptide Comparisons
For Research Use Only (RUO). This comparison is for educational and informational purposes only. All products are intended solely for in-vitro research and laboratory experimentation. Products have not been approved by the FDA for human or veterinary use. Pure U.S. Peptides does not condone or encourage the use of these products for anything other than strictly defined research applications.